tiprankstipranks
Anavex Life Sciences (GB:0HFR)
LSE:0HFR
Holding GB:0HFR?
Track your performance easily

Anavex Life Sciences (0HFR) Earnings Dates, Call Summary & Reports

0 Followers

Earnings Data

Report Date
Feb 06, 2025
TBA Not Confirmed
Period Ending
2025 (Q1)
Consensus EPS Forecast
-$0.15
Last Year’s EPS
-$0.11
Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---

Earnings Call Summary

Earnings Call Date:Dec 23, 2024
|
% Change Since: 53.04%
|
Next Earnings Date:Feb 06, 2025
Earnings Call Sentiment|Positive
The earnings call reflected a generally positive outlook with significant advancements in Alzheimer's treatment development and strong financial positioning. However, the company reported a net loss for the quarter.
Company Guidance
During the Anavex Life Sciences Q4 2024 earnings call, several key metrics and updates were shared, particularly regarding their Alzheimer's treatment, blarcamesine. The European Medicines Agency (EMA) accepted the marketing authorization application for blarcamesine, supported by data from the Phase IIb/III ANAVEX-004 trial and its 144-week open-label extension, ATTENTION-AD. Financially, Anavex reported a cash position of $132.2 million as of September 30, 2024, with no debt, and a quarterly net loss of $11.6 million, or $0.14 per share. Research and development expenses were $11.6 million, while general and administrative expenses stood at $2.8 million. The company anticipates its current cash reserves will provide a runway of approximately four years. Additionally, Anavex plans to present top-line data from the ATTENTION-AD trial at the JPMorgan 2025 Healthcare Conference, further demonstrating their commitment to advancing innovative treatment options.
EMA Acceptance for Blarcamesine
The European Medicines Agency (EMA) has accepted for review the marketing authorization application (MAA) for blarcamesine for the treatment of Alzheimer's disease. This submission is backed by data from the Phase IIb/III ANAVEX-004 trial and a 144-week open-label extension entitled study ATTENTION-AD, potentially bringing the company closer to offering a new treatment option in Europe.
Upcoming Presentation at JPMorgan 2025 Healthcare Conference
Anavex announced its upcoming presentation of top line long-term data from the ATTENTION-AD open-label extension trial at the JPMorgan 2025 Healthcare Conference in January 2025.
Publication of Blarcamesine Data
A peer-reviewed manuscript titled blarcamesine for the treatment of early Alzheimer's disease from the ANAVEX2-73-AD-004 Phase II/III trial has been accepted for publication in a medical journal focused on Alzheimer's disease.
Encouraging Preliminary EEG Biomarker Results for ANAVEX 3-71
Anavex announced encouraging preliminary EEG biomarker results from Part A of the ongoing placebo-controlled Phase II clinical study of ANAVEX 3-71 for the treatment of schizophrenia, demonstrating a dose-dependent effect on two key EEG biomarkers.
Strong Financial Position
Anavex reported a cash position of $132.2 million with no debt, and a cash utilization rate indicating a runway of approximately 4 years.
---

Anavex Life Sciences (GB:0HFR) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

GB:0HFR Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Feb 06, 20252025 (Q1)
-0.15 / -
-0.11
Dec 23, 20242024 (Q4)
-0.16 / -0.14
-0.12-16.67% (-0.02)
Aug 06, 20242024 (Q3)
-0.16 / -0.14
-0.140.00% (0.00)
May 09, 20242024 (Q2)
-0.11 / -0.13
-0.1723.53% (+0.04)
Feb 07, 20242024 (Q1)
-0.14 / -0.11
-0.1735.29% (+0.06)
Nov 27, 20232023 (Q4)
-0.15 / -0.12
-0.1833.33% (+0.06)
Aug 08, 20232023 (Q3)
-0.17 / -0.14
-0.1612.50% (+0.02)
May 09, 20232023 (Q2)
-0.19 / -0.17
-0.14-21.43% (-0.03)
Feb 07, 20232023 (Q1)
-0.19 / -0.17
-0.14-21.43% (-0.03)
Nov 28, 20222022 (Q4)
-0.17 / -0.18
-0.16-12.50% (-0.02)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---

GB:0HFR Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Dec 23, 2024$8.63$11.38+31.90%
Aug 06, 2024$6.57$6.94+5.71%
May 09, 2024$3.69$3.80+2.98%
Feb 07, 2024$5.53$5.75+3.98%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---

FAQ

When does Anavex Life Sciences (GB:0HFR) report earnings?
Anavex Life Sciences (GB:0HFR) is schdueled to report earning on Feb 06, 2025, TBA Not Confirmed.
    What is Anavex Life Sciences (GB:0HFR) earnings time?
    Anavex Life Sciences (GB:0HFR) earnings time is at Feb 06, 2025, TBA Not Confirmed.
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is the P/E ratio of Anavex Life Sciences stock?
          The P/E ratio of Anavex Life Sciences is N/A.
            What is GB:0HFR EPS forecast?
            GB:0HFR EPS forecast for the fiscal quarter 2025 (Q1) is -$0.15.
              ---

              Anavex Life Sciences (GB:0HFR) Earnings News

              Anavex Shares (NASDAQ: AVXL) Plunge after Q4 Earnings Miss
              Premium
              Uncategorized
              Anavex Shares (NASDAQ: AVXL) Plunge after Q4 Earnings Miss
              2y ago
              What am I Missing?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis